HIV Infections Clinical Trial
Official title:
Implementation and Evaluation of a Community-Based Model for Delivery of Antiretroviral Therapy in Cambodia: A Quasi-Experimental Study
The community-based ART delivery (CAD) model will build on the existing framework to engage community action, operationalized in the current Global Fund-supported project. Community Action Workers (CAW), who are assigned to ART centers and conduct outreach work, are well-suited to administer CAD scheme. KHANA and the project partners all have implementation roles in the Global Fund-supported project and established working channels with the CAW. While the previous experiences suggest the CAD model's effectiveness, implementing it in Cambodia requires adaptation to its specific local context. The proposed project will be implemented as an implementation study in nine ART sites and supported by a concrete evaluation plan. KHANA Center for Population Health Research will lead the research component. The project has three strategic areas and corresponding deliverables as follows: A. The development of a locally-fitted model: bringing ART closer to the people living with HIV B. The research: formulation, evaluation, documentation, and dissemination of the evidence, knowledge, and lessons learned C. The scale-up: advocacy for the SOP development to replicate/scale-up the CAD model The project will benefit a wide range of stakeholders. The approximately 2,000 ART clients enrolled in the nine selected clinics will face less cost, time, and discrimination, which will also benefit their families. The clinics will have a reduced workload on site, and they would be able to improve the quality of care for the visiting clients. The Cambodian health system will obtain a CAD model tailored to the country's local context and develop Standard Operating Procedures for the scheme with readily involved stakeholders. The scale-up of the model will benefit all other ART clinics and clients in the country. The 36-months project starting from June 1, 2019, will include six months of start-up and baseline assessments, 24-month intervention, and six-month evaluation.
Status | Recruiting |
Enrollment | 4102 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years and older |
Eligibility | Inclusion criteria: 1. Receiving ART for at least one year. 2. No adverse drug reactions or ARV drug interactions requiring regular monitoring. 3. No suspected or confirmed tuberculosis, no other opportunistic infections, and not on any prophylaxis. 4. Not pregnant/breastfeeding (for women). 5. Having a good understanding of lifelong treatment and adherence to the medication. 6. Presenting with evidence of treatment success: two consecutive undetectable viral load measures (or, in the absence of viral load monitoring, CD4 counts above 200 cells/mm3 and objective adherence measure). 7. Aged =15 years. 8. On the first-line ARV regimen. Exclusion criteria 1. Unstable people living with HIV as defined above 2. Mobile populations |
Country | Name | City | State |
---|---|---|---|
Cambodia | Cambodia Anti-Tuberculosis Association | Phnom Penh | |
Cambodia | KHANA Center for Population Health Research | Phnom Penh | |
Cambodia | National Center for Tuberculosis and Leprosy Control | Phnom Penh |
Lead Sponsor | Collaborator |
---|---|
National University of Singapore | KHANA Center for Population Health Research |
Cambodia,
Bemelmans M, Baert S, Goemaere E, Wilkinson L, Vandendyck M, van Cutsem G, Silva C, Perry S, Szumilin E, Gerstenhaber R, Kalenga L, Biot M, Ford N. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health. — View Citation
Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Barnighausen T. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS. 2014 Mar;28 Suppl 2:S187-204. doi: 10.1097/QAD.0000000000000252. — View Citation
Chhim K, Mburu G, Tuot S, Sopha R, Khol V, Chhoun P, Yi S. Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study. AIDS Res Ther. 2018 Nov 17;15(1):20. doi: 10.1186/s12981-018-0205-z. — View Citation
Decroo T, Koole O, Remartinez D, dos Santos N, Dezembro S, Jofrisse M, Rasschaert F, Biot M, Laga M. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health. 2014 May;19(5):514-21. — View Citation
Decroo T, Rasschaert F, Telfer B, Remartinez D, Laga M, Ford N. Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. Int Health. 2013 Sep;5 — View Citation
Decroo T, Telfer B, Dores CD, White RA, Santos ND, Mkwamba A, Dezembro S, Joffrisse M, Ellman T, Metcalf C. Effect of Community ART Groups on retention-in-care among patients on ART in Tete Province, Mozambique: a cohort study. BMJ Open. 2017 Aug 11;7(8): — View Citation
Faturiyele IO, Appolinare T, Ngorima-Mabhena N, Fatti G, Tshabalala I, Tukei VJ, Pisa PT. Outcomes of community-based differentiated models of multi-month dispensing of antiretroviral medication among stable HIV-infected patients in Lesotho: a cluster ran — View Citation
Ibrahim AA, Akindele MO, Ganiyu SO, Kaka B, Abdullahi BB, Sulaiman SK, Fatoye F. The Hausa 12-item short-form health survey (SF-12): Translation, cross-cultural adaptation and validation in mixed urban and rural Nigerian populations with chronic low back — View Citation
Jay S, Litt IF, Durant RH. Compliance with therapeutic regimens. J Adolesc Health Care. 1984 Apr;5(2):124-36. doi: 10.1016/s0197-0070(84)80012-1. — View Citation
Moudachirou R, Van Cutsem G, Chuy RI, Tweya H, Senkoro M, Mabhala M, Zolfo M. Retention and sustained viral suppression in HIV patients transferred to community refill centres in Kinshasa, DRC. Public Health Action. 2020 Mar 21;10(1):33-37. doi: 10.5588/p — View Citation
Murray KR, Dulli LS, Ridgeway K, Dal Santo L, Darrow de Mora D, Olsen P, Silverstein H, McCarraher DR. Improving retention in HIV care among adolescents and adults in low- and middle-income countries: A systematic review of the literature. PLoS One. 2017 — View Citation
Mutasa-Apollo T, Ford N, Wiens M, Socias ME, Negussie E, Wu P, Popoff E, Park J, Mills EJ, Kanters S. Effect of frequency of clinic visits and medication pick-up on antiretroviral treatment outcomes: a systematic literature review and meta-analysis. J Int — View Citation
Okoboi S, Ding E, Persuad S, Wangisi J, Birungi J, Shurgold S, Kato D, Nyonyintono M, Egessa A, Bakanda C, Munderi P, Kaleebu P, Moore DM. Community-based ART distribution system can effectively facilitate long-term program retention and low-rates of deat — View Citation
Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol. 1993 Sep 30;72(10):68D-74D. doi: 10.1016/0002-9149(93)90014-4. — View Citation
Rasschaert F, Decroo T, Remartinez D, Telfer B, Lessitala F, Biot M, Candrinho B, Van Damme W. Adapting a community-based ART delivery model to the patients' needs: a mixed methods research in Tete, Mozambique. BMC Public Health. 2014 Apr 15;14:364. doi: — View Citation
Rivers PA, Glover SH. Health care competition, strategic mission, and patient satisfaction: research model and propositions. J Health Organ Manag. 2008;22(6):627-41. doi: 10.1108/14777260810916597. — View Citation
Tuot S, Teo AKJ, Cazabon D, Sok S, Ung M, Ly S, Choub SC, Yi S. Acceptability of active case finding with a seed-and-recruit model to improve tuberculosis case detection and linkage to treatment in Cambodia: A qualitative study. PLoS One. 2019 Jul 2;14(7):e0210919. doi: 10.1371/journal.pone.0210919. eCollection 2019. — View Citation
Yi S, Chhoun P, Suong S, Thin K, Brody C, Tuot S. AIDS-related stigma and mental disorders among people living with HIV: a cross-sectional study in Cambodia. PLoS One. 2015 Mar 25;10(3):e0121461. doi: 10.1371/journal.pone.0121461. eCollection 2015. — View Citation
* Note: There are 18 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent of people living with HIV with viral suppression | Viral load At least 90% of participants in intervention arm will have a viral load <1000 RNA copies/mL by the endline of the intervention | 24 months after the intervention started | |
Primary | Percent of people living with HIV who remained in HIV care and treatment | At least 90% of participants in the intervention will be retained in care and treatment 12 months after the treatment started | 24 months after the intervention started | |
Primary | Percent of people living with HIV with good adherence to ART | At least 90% of the participants in the intervention will report good adherence to ART at the endline. | 24 months after the intervention started | |
Primary | Percent of healthcare providers at ART clinics who reported reduced workload | Workload at ART clinics will be self-reported by health care workers providing ART services at the clinics. The investigators hypothesize that a significantly higher proportion of health care providers at ART clinics under the CAD intervention arm will agree that their workload has been reduced at endline compared to baseline. | 24 months after the intervention started | |
Secondary | Cost-effectiveness of community-based ART delivery (CAD) model intervention | For the cost-effectiveness analyses, direct and indirect medical costs for follow-up care and ARV refills will be collected. The costs in this community-based ART delivery intervention will be compared with the costs in standard care services (facility-based and multi-month dispensing model). The investigators anticipated that the community-based ART delivery intervention will be similar in all intervention and service delivery models. However, CAD model will help save time and costs of people living with HIV in the intervention arm. | 24 months after the intervention started | |
Secondary | Percent of people living with HIV who reported improved quality of life | The quality of life of people living with HIV will be measured using WHO's Quality of Life HIV brief questionnaire (WHOQOL-HIV-BREF). The scale's domain score ranges from 4 to 20. Higher scores indicate a better quality of life. The investigators hypothesized that the proportion of people living with HIV who reported a higher quality of life would increase more significantly from baseline to endline among participants in the community-based ART delivery (CAD) intervention arm than those in the control arm. | 24 months after the intervention started | |
Secondary | Percent of people living with HIV who reported improved mental health | The mental health of people living with HIV will be measured using the Center for Epidemiologic Studies Depression Scale (CES-D). The total CES-D score ranges from 0 to 60. A subject with a CES-D score of =16 will be defined as having depressive symptoms. The investigators hypothesized that the proportion of people living with HIV who reported having depressive symptoms would decrease more significantly from baseline to endline among participants in the community-based ART delivery (CAD) intervention arm than in the control arm. | 24 months after the intervention started | |
Secondary | Percent of people living with HIV who reported improved social support health | Social support for people living with HIV will be measured using Berlin Social Support Scale (BSSS). The BSSS's total score ranges from 15 to 60, with higher scores indicating higher social support. The investigators hypothesized that the proportion of people living with HIV who perceived a high social support level would increase more significantly from baseline to endline among participants in the community-based ART delivery (CAD) intervention arm than those in the control arm. | 24 months after the intervention started |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |